Research programme: bispecific molecule therapeutics - Alligator Bioscience/MacroGenics
Latest Information Update: 28 May 2025
At a glance
- Originator Alligator Bioscience; MacroGenics
- Class Antineoplastics; Immunotherapies
- Mechanism of Action T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2025 No recent reports of development identified for research development in Cancer in Sweden (Parenteral)
- 28 May 2025 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 15 Apr 2021 Alligator Bioscience and MacroGenics agree to co-develop bispecific molecule therapeutics for Cancer